C-reactive protein and cardiovascular disease: A critical appraisal

Current Opinion in Cardiology

Volumn 20, Issue 5, 2005, Pages 407-416

  Sepulveda, Jorge L ^a   Mehta, Jawahar L ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Atherosclerosis; C reactive protein; Cardiovascular risk; Inflammation; Mechanisms

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; NITRIC OXIDE;

ATHEROGENESIS; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; DISEASE COURSE; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; OBESITY; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; REVIEW; RISK FACTOR;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPROTEINS; NITRIC OXIDE;

EID: 23944495086     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000175518.57804.94     Document Type: Review

References (100)

1. Tillett W, Francis TJ. Serological reactions in pneumonia with a non protein somatic fraction of pneumococcus. J Exp Med 1930; 52:561-585.
2. Ivashchenko Y, Kramer F, Schafer S, et al. Protein kinase C pathway is involved in transcriptional regulation of C-reactive protein synthesis in human hepatocytes. Arterioscler Thromb Vasc Biol 2005; 25:186-192.
3. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 2005; 166:1265-1271.
4. Maier W, Altwegg LA, Corti R, et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005; 111: 1355-1361. Levels of interleukin-6 and serum amyloid A but not CRP were increased at the site of plaque rupture and in the aorta in patients with acute myocardial infarction. CRP was found in the cytoplasm of monocytes in the thrombus.
5. Szalai AJ. C-reactive protein (CRP) and autoimmune disease: facts and conjectures. Clin Dev Immunol 2004; 11:221-226.
6. Rodriguez W, Mold C, Kataranovski M, et al. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum 2005; 52:642-650. This paper provides strong evidence for a protective role of CRP against autoimmunity.
7. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005; 14:33-37. This is an excellent review of the effects of CRP on vascular cells.
8. Labarrere CA, Zaloga GP. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 2004; 117:499-507.
9. Wang HR, Li JJ, Huang CX, Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 2005; 353: 53-60.
10. Lim MY, Wang H, Kapoun AM, et al. p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells. J Mol Cell Cardiol 2004; 37:1111-1114.
11. Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 2004; 36: 405-410.
12. Wang Q, Zhu X, Xu Q, et al. Effect of C-reactive protein on gene expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol 2004.
13. Khreiss T, Jozsef L, Potempa LA, Filep JG. Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation 2004; 110:2713-2720.
14. Han KH, Hong KH, Park JH, et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004; 109: 2566-2571. This well-controlled study showed binding of CRP to monocytes, resulting in upregulation of the CCR2 receptor and induction of strong chemotaxis mediated by monocyte chemoattractant protein-1.
15. Lin R, Liu J, Gan W, Yang G. C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Biol Pharm Bull 2004; 27:1537-1543.
16. Heuertz RM, Schneider GP, Potempa LA, Webster RO. Native and modified C-reactive protein bind different receptors on human neutrophils. Int J Biochem Cell Biol 2005; 37:320-335. This article shows that modified CRP has different effects than those of native CRP.
17. Williams TN, Zhang CX, Game BA, et al. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol 2004; 24:61-66.
18. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105:1890-1896.
19. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783-1790.
20. Blaschke F, Bruemmer D, Yin F, et al. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004; 110: 579-587.
21. Nagoshi Y, Kuwasako K, Cao YN, et al. Effects of C-reactive protein on atherogenic mediators and adrenomedullin in human coronary artery endothelial and smooth muscle cells. Biochem Biophys Res Commun 2004; 314: 1057-1063. This study distinguishes the effects on endothelial cells and smooth muscle cells caused by CRP compared with endotoxin contamination and reports that decreased adrenomedullin may mediate increased vascular oxidative stress.
22. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109:2058-2067.
23. Suh W, Kim KL, Choi JH, et al. C-reactive protein impairs angiogenic functions and decreases the secretion of arteriogenic chemo-cytokines in human endothelial progenitor cells. Biochem Biophys Res Commun 2004; 321: 65-71.
24. Clapp BR, Hirschfield GM, Storry C, et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 2005; 111:1530-1536. This is a well-controlled study of the effects of CRP on NO availability in the endothelial cells of rats and humans. CRP increased NO availability by upregulating the transcription of GTPCH-1, a rate-limiting enzyme in the synthesis of tetrahydrobiopterin. The specificity of CRP is controlled by specific absorption and binding inhibitor RMM.
25. Qamirani E, Ren Y, Kuo L, Hein TW. C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2005; 25: 995-1001.
26. Paffen E, Vos HL, Bertina RM. C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler Thromb Vasc Biol 2004; 24: 975-981. This study shows that other peripheral blood mononuclear cells mediate induction of tissue factor in monocytes by CRP.
27. van den Berg CW, Taylor KE, Lang D. C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol 2004; 24:e168-e171.
28. Lafuente N, Azcutia V, Matesanz N, et al. Evidence for sodium azide as an artifact mediating the modulation of inducible nitric oxide synthase by C-reactive protein. J Cardiovasc Pharmacol 2005; 45:193-196.
29. Swafford AN, Bratz IN, Knudson JD, et al. C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. Am J Physiol Heart Circ Physiol 2005; 288: H1786-H1795.
30. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805-1812.
31. Ikeda U, Takahashi M, Shimada K. C-reactive protein directly inhibits nitric oxide production by cytokine-stimulated vascular smooth muscle cells. J Cardiovasc Pharmacol 2003; 42:607-611.
32. Popovic N, Popovic M, Jovanova-Nesic K, et al. Effect of neural transplantation on depressive behavior in rats with lesioned nucleus basalis magnocellularis. Int J Neurosci 2002; 112:105-115.
33. Fichtischerer S, Breuer S, Schachinger V, et al. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J 2004; 25:1412-1418. In this study, CRP levels correlated with reduced NO bioavailability as measured by forearm blood in response to L-NG-Monomethyl-L-arginine (L-NMMA).
34. Lee DH, Jacobs DR Jr. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 2005; 178:327-330.
35. Abramson JL, Hooper WC, Jones DP, et al. Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis 2005; 178:115-121.
36. van Tits L, de Graaf J, Toenhake H, et al. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 2005; 25: 717-722.
37. Bhakdi S, Torzewski M, Paprotka K, et al. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteine halts before detrimental terminal sequence. Circulation 2004; 109: 1870-1876. This was a study of complement activation by enzymatically modified LDL and CRP. CRP initiates complement activation to opsonize E-LDL but prevents completion of the complement cascade. At high concentrations, E-LDL can fully activate complement in the absence of CRP.
38. Paul A, Ko KW, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109: 647-655.
39. Buffon A, Biasucci LM, Liuzzo G, et al. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347:5-12.
40. Cusack MR, Marber MS, Lambiase PD, et al. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 2002; 39: 1917-1923.
41. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002; 39:632-637.
42. Folsom AR, Pankow JS, Tracy RP, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001; 88: 112-117.
43. Navarro Estrada JL, Gabay JM, Alvarez J, et al. Relation of C-reactive protein to extent and complexity of coronary narrowing in patients with non-ST elevation acute coronary syndromes: a prospective cohort study. Coron Artery Dis 2004; 15:477-484. This large study of 1253 CAD patients showed that CRP is associated with major adverse cardiovascular events within 6 months but not with the extent and complexity of coronary atherosclerosis.
44. Bisoendial RJ, Kastelein JJ, Levels JH, et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96:714-716. This was the first study to inject CRP in human volunteers and demonstrated activation of inflammatory markers (interleukin-6 and serum amyloid A within 4 hours) as well as prothrombotic molecules (PAM, prothrombin fragments).
45. Saigo M, Waters DD, Abe S, et al. Soluble fibrin, C-reactive protein, fibrinogen, factor VII, antithrombin, proteins C and S, tissue factor, D-dimer, and prothrombin fragment 1 + 2 in men with acute myocardial infarction
46. Speidl WS, Zeiner A, Nikfardjam M, et al. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J Am Coll Cardiol 2005; 45:30-34. This study of 50 patients 6 months after acute myocardial infarction showed correlation of CRP levels with impaired fibrinolytic response to venous occlusion.
47. Zouaoui Boudjeltia K, Piagnerelli M, Brohee D, et al. Relationship between CRP and hypofibrinolysis: is this a possible mechanism to explain the association between CRP and outcome in critically ill patients? Thromb J 2004; 2:7.
48. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
49. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 2003; 49:1258-1271.
50. Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005; 352:1611-1613. This was a large-scale study of the distribution of CRP among adults in the United States.
51. Persson GR, Pettersson T, Ohlsson O, Renvert S. High-sensitivity serum C-reactive protein levels in subjects with or without myocardial infarction or periodontitis. J Clin Periodontol 2005; 32:219-224. This article shows the association of elevated CRP with periodontitis in individuals without CAD.
52. Roberts WL. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: laboratory tests available to assess inflammation -performance and standardization: a background paper. Circulation 2004; 110:e572-e576. This article reviews the analytic issues for high-sensitivity measurement of CRP.
53. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397. This article reports a study of CRP levels in 2459 patients who experienced major adverse cardiovascular events in comparison with a matched cohort of 3969 individuals who did not. After adjustment for many known risk factors, CRP showed an odds ratio for CAD of 1.45. A similar conclusion was reached after meta-analysis involving a total of 7068 patients with CAD.
54. Rogowski O, Toker S, Shapira I, et al. Values of high-sensitivity C-reactive protein in each month of the year in apparently healthy individuals. Am J Cardiol 2005; 95:152-155.
55. Pearson TA, Bazzarre TL, Daniels SR, et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003; 107:645-651.
56. MacGregor AJ, Gallimore JR, Spector TD, Pepys MB. Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem 2004; 50:130-134. This study of risk factors in monozygotic compared with dizygotic twins demonstrated a genetic component for the regulation of CRP levels.
57. Suk HJ, Ridker PM, Cook NR, Zee RY. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis 2005; 178: 139-145.
58. Kovacs A, Green F, Hansson LO, et al. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 2005; 178:193-198.
59. D'Aiuto F, Casas JP, Shah T, et al. C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis 2005; 179:413-417.
60. Judson R, Brain C, Dain B, et al. New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis 2004; 177:345-351.
61. Marz W, Scharnagl H, Hoffmann MM, et al. The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Eur Heart J 2004; 25:2109-2119.
62. Araujo F, Pereira AC, Mota GF, et al. The influence of tumor necrosis factor - 308 and C-reactive protein G1059C gene variants on serum concentration of C-reactive protein: evidence for an age-dependent association. Clin Chim Acta 2004; 349:129-134.
63. Rogowski O, Zeltser D, Shapira I, et al. Gender difference in C-reactive protein concentrations in individuals with atherothrombotic risk factors and apparently healthy ones. Biomarkers 2004; 9:85-92.
64. Bertran N, Camps J, Fernandez-Ballart J, et al. Diet and lifestyle are associated with serum C-reactive protein concentrations in a population-based study. J Lab Clin Med 2005; 145:41-46.
65. Khor LL, Muhlestein JB, Carlquist JF, et al. Sex- and age-related differences in the prognostic value of C-reactive protein in patients with angiographic coronary artery disease. Am J Med 2004; 117:657-664.
66. Anand SS, Razak F, Yi Q, et al. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol 2004; 24:1509-1515.
67. Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol 2004; 93:1238-1242.
68. Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem 2004; 50:574-581.
69. Sattar N, McConnachie A, O'Reilly D, et al. Inverse association between birth weight and C-reactive protein concentrations in the MIDSPAN Family Study. Arterioscler Thromb Vasc Biol 2004; 24:583-587.
70. Ajani UA, Ford ES, Mokdad AH. Prevalence of high C-reactive protein in persons with serum lipid concentrations within recommended values. Clin Chem 2004; 50:1618-1622.
71. Khaodhiar L, Ling PR, Blackburn GL, Bistrian BR. Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. JPEN J Parenter Enteral Nutr 2004; 28: 410-415.
72. Aronson D, Bartha P, Zinder O, et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004; 28:674-679. This study of 1929 apparently healthy individuals shows that body mass index accounts for 15% of the variability in CRP levels, compared with triglycerides, high-density lipoprotein cholesterol (inversely), and fasting blood glucose levels, which accounts for approximately 1% of CRP variability.
73. Lee WY, Park JS, Noh SY, et al. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 2004; 97:101-106.
74. Rutter MK, Meigs JB, Sullivan LM, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110:380-385. In this study, both the metabolic syndrome and CRP independently predicted CAD in 3037 individuals.
75. Laaksonen DE, Niskanen L, Nyyssonen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47:1403-1410.
76. Aronson D, Bartha P, Zinder O, et al. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med 2004; 21:39-44.
77. Larkin EK, Rosen CL, Kirchner HL, et al. Variation of C-reactive protein levels in adolescents: association with sleep-disordered breathing and sleep duration. Circulation 2005; 111:1978-1984.
78. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290:502-510.
79. Wells BJ, Mainous AG 3rd, Everett CJ. Association between dietary arginine and C-reactive protein. Nutrition 2005; 21:125-130.
80. Ahmad I, Zhan M, Miller M. High prevalence of C-reactive protein elevation with normal triglycerides (100-149 mg/dL): are triglyceride levels below 100 mg/dL more optimal in coronary heart disease risk assessment? Am J Med Sci 2005; 329:173-177. Triglyceride levels of 100 to 150 mg/dl, within the reference range, were as strongly associated with elevated CRP as triglyceride levels >150 mg/dl, even in individuals with normal body mass index.
81. Aronson D, Sheikh-Ahmad M, Avizohar O, et al. C-Reactive protein is inversely related to physical fitness in middle-aged subjects. Atherosclerosis 2004; 176:173-179.
82. Okita K, Nishijima H, Murakami T, et al. Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thromb Vasc Biol 2004; 24:1868-1873.
83. Obisesan TO, Leeuwenburgh C, Phillips T, et al. C-reactive protein genotypes affect baseline, but not exercise training-induced changes, in C-reactive protein levels. Arterioscler Thromb Vasc Biol 2004; 24:1874-1879.
84. Albert MA, Glynn PJ, Ridker PM. Effect of physical activity on serum C-reactive protein. Am J Cardiol 2004; 93:221-225.
85. Stauffer BL, Hoetzer GL, Smith DT, DeSouza CA. Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy. J Appl Physiol 2004; 96:143-148.
86. Wunder DM, Kretschmer R, Bersinger NA. Concentrations of leptin and C-reactive protein in serum and follicular fluid during assisted reproductive cycles. Hum Reprod 2005; 20:1266-1271.
87. Tuzcu A, Bahceci M, Gokalp D, et al. Subclinical hypothyroidism may be associated with elevated high-sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr J 2005; 52:89-94.
88. Jublanc C, Bruckert E, Giral P, et al. Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP. Atherosclerosis 2004; 172:7-11.
89. Lee WY, Suh JY, Rhee EJ, et al. Plasma CRP, apolipoprotein A-1, apolipoprotein B and Lpa levels according to thyroid function status. Arch Med Res 2004; 35:540-545.
90. Smith GD, Lawlor DA, Harbord R, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005; 25: 1051-1056.
91. Suarez EC. C-reactive protein is associated with psychological risk factors of cardiovascular disease in apparently healthy adults. Psychosom Med 2004; 66:684-691.
92. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2004; 164:1010-1014.
93. Douglas KM, Taylor AJ, O'Malley PG. Relationship between depression and C-reactive protein in a screening population. Psychosom Med 2004; 66: 679-683.
94. Meier-Ewert HK, Ridker PM, Rifai N, et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol 2004; 43:678-683.
95. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565.
96. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109:1955-1959. This article reports a study of 27,939 apparently healthy women and shows linear correlation between levels of CRP and risk of major adverse cardiovascular events, even after adjustment for conventional risk factors. All the data are presented as relative risks.
97. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159:882-890. This article shows that epidemiologic risk studies using odds ratios or relative risks are important for public health measures or to generate hypothesis; however, a test intended for screening, for diagnosis, or to guide therapy requires good sensitivity, specificity, and predictive values. The article shows tables and examples relating odds ratios to sensitivity and specificity.
98. Levinson SS, Miller JJ, Elin RJ. Poor predictive value of high-sensitivity C-reactive protein indicates need for reassessment. Clin Chem 2004; 50:1 733-1 735. This article reports a re-examination of cohort studies of CRP as a predictor of CAD in apparently healthy individuals, showing very low positive predictive values.
99. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28. This randomized controlled trial of two regimens of statin treatment in 3745 patients with acute coronary syndrome shows an association between reduction of CRP levels after statin treatment and outcome.
100. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38. This randomized controlled trial of two regimens of statin treatment in 502 patients with CAD shows that the higher-intensity statin treatment results in lower CRP levels and reduces progression of CAD.